Multiple Myeloma

Multiple Myeloma

BCMA-Directed CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma

In the phase Ib/II CARTITUDE-1 trial reported in The Lancet, Dr Berdeja and colleagues found that ciltacabtagene autoleucel produced a high rate of durable and deep responses...

The ASCO Post
Study Finds Response to COVID-19 Vaccination Varies Widely in Patients With Multiple Myeloma

Patients with MM had a wide variety of responses to COVID-19 vaccines—in some cases, no detectable response at all—pointing to the need for antibody testing and precautions...

The ASCO Post
Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression

Study investigators define incidence and risk factors of ONJ and explore oral microbial signatures and host immune response as reflected by cytokine changes in saliva and serum in MM patients...

Frontiers in Oncology

SMAD1 as a Biomarker and Potential Therapeutic Target in Drug-Resistant Multiple Myeloma

Study investigators aim to examine if SMAD1 plays an important role in multiple myeloma pathogenesis and can serve as a therapeutic target.

Biomarker Research
Overall Survival Benefit With Upfront Daratumumab Plus Lenalidomide/Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma

The addition of daratumumab to lenalidomide and dexamethasone result in a statistically significant OS benefit over lenalidomide/dexamethasone alone in patients with newly diagnosed MM who are inel

The ASCO Post
Mobile Wearable Devices Show Some Sleep Disturbances During Multiple Myeloma Treatment

In a prospective study, mobile wearable devices showed no significant gains or losses in overall sleep trends over time among patients receiving treatment for multiple myeloma.

Cancer Therapy Advisor
Iberdomide-Based Regimens Show Promise in Relapsed/Refractory Multiple Myeloma

Among heavily pretreated patients with R/R MM, iberdomide-based regimens appear to yield promising safety and efficacy outcomes, supporting further study of this therapy, per research presented at

Cancer Therapy Advisor
As Novel Therapies for Newly Diagnosed Multiple Myeloma Emerge, Researchers Question the Value of Standard-of-Care Autologous Stem Cell Transplant

These findings, presented during the 2021 ASCO Annual Meeting, call into question the advantages of the upfront ASCT approach in newly diagnosed MM.

ASCO Daily News
CHEK1 and circCHEK1_246aa Evoke Chromosomal Instability and Induce Bone Lesion Formation in Multiple Myeloma

Multiple myeloma is still incurable and characterized by clonal expansion of plasma cells in the bone marrow.

Molecular Cancer
The Influence of High-Efficiency Particulate Air Filtration on Mortality Among Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Autologous stem cell transplantation continues to be the standard treatment for transplant-eligible multiple myeloma patients.

Scientific Reports
Health-Related Quality of Life in Patients With Newly Diagnosed Multiple Myeloma Ineligible for Stem Cell Transplantation: Results From the Randomized Phase III ALCYONE Trial

In the phase III ALCYONE trial, D-VMP significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multipl

BMC Cancer
Genome-Wide Identification of Potential Biomarkers in Multiple Myeloma Using Meta-Analysis of mRNA and miRNA Expression Data

Differentially expressed genes and miRNAs in MM may influence disease pathogenesis, clinical presentation / drug sensitivities.

Scientific Reports
Idecabtagene Vicleucel Approved for Relapsed or Refractory Multiple Myeloma

The FDA has approved ide-cel as the first BCMA-directed CAR T-cell therapy for the treatment of adult patients with R/R MM who have received four or more prior lines of therapy, including...

ASH Clinical News
Potent Preclinical Activity of HexaBody-DR5/DR5 in Relapsed and/or Refractory Multiple Myeloma

This study explores the preclinical activity of HexaBody-DR5/DR5 in multiple myeloma, because MM cells are known to express DR5.

Blood Advances
Frail Patients With Newly Diagnosed Multiple Myeloma: Triplet Regimen

Stege et al find that a regimen of Ixa-Dara-dex is associated with a high response rate in frail patients with newly diagnosed MM, but also a high rate of early discontinuation of treatment and...<

The ASCO Post
Comprehensive CRISPR-Cas9 Screens Identify Genetic Determinants of Drug Responsiveness in Multiple Myeloma

The introduction of new drugs in the past years has substantially improved outcome in multiple myeloma.

Blood Advances
Preclinical Activity and Determinants of Response of the GPRC5DxCD3 Bispecific Antibody Talquetamab in Multiple Myeloma

Talquetamab, the new GPRC5DxCD3 bispecific antibody, actively kills GPRC5D+ MM cell lines and primary MM cells in vitro.

Blood Advances
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma

The goal of this review is to summarize the understanding of the problem of resistance to these drugs, which is ultimately responsible for patient fatality.

Pathway-Directed Therapy in Multiple Myeloma

There are several pathways that can be targeted in myeloma, and, in combination with personalized medicine, some have shown promising results. 

Immunological Prognostic Factors in Multiple Myeloma

The authors focus on characterizing the components of the immune system that are of prognostic value in MM patients, in order to facilitate the development of...

International Journal of Molecular Sciences
Employment of Artificial Intelligence Based on Routine Laboratory Results for the Early Diagnosis of Multiple Myeloma

In order to enhance the detection rate of multiple myeloma and execute an early and more precise disease management, an artificial intelligence assistant diagnosis system is developed.

Frontiers in Oncology
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

The intent of this paper is to summarize the current major results of monoclonal antibody treatments in multiple myeloma.

The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges

Here, authors provide a critical review of the literature on the role of lipids and lipoproteins in MM pathophysiology.

Frontiers in Oncology
Melphalan Flufenamide Receives Accelerated Approval for Relapsed/Refractory Multiple Myeloma

Melphalan flufenamide, in combination with dexamethasone, has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory MM who have received...

ASH Clinical News
Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

Study investigators examine the distribution of different subsets of monocytes in blood and bone marrow of newly-diagnosed untreated MGUS, smoldering and active MM, and its relationship with...

Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models

This study investigates the prognostic value of circulating plasma cells and establish novel nomograms to predict individual PFS as well as OS of patients with newly diagnosed multiple myeloma.

Frontiers in Oncology
Targeting Phosphoinositide 3-Kinases and Histone Deacetylases in Multiple Myeloma

Because the histone deacetylase and phosphoinositide 3-kinase pathway is a key signal in cancer cell biology, study investigators examine whether dual HDAC and PI3K inhibitors...

Experimental Hematology & Oncology
Study Highlights Need to Protect Multiple Myeloma Patients From Infection

While there have been significant advancements in multiple myeloma treatment, infections—particularly bacterial and viral—remain major causes of morbidity and mortality among these patients...

Oncology Times - Latest Articles
Reovirus-Induced Cell-Mediated Immunity for the Treatment of Multiple Myeloma Within the Resistant Bone Marrow Niche

This study uses human peripheral blood mononuclear cells from healthy donors and in vitro co-culture of MM cells and BM stromal cells to recapitulate the resistant BM niche.

Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression

This review summarizes the main cellular and molecular alterations observed in MM patients’ immune system. 

Boosting Immunity Against Multiple Myeloma

This review focuses on current and future immunotherapies used in multiple myeloma with impact on bone marrow immune microenvironment cells, also known as the bone marrow immunome.

HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients

This study evaluates the impact of the HLC pair suppression on the rate of bloodstream infections and early death in 115 newly diagnosed MM patients.

Frontiers in Oncology
Multiple Myeloma: MMRF CureCloud Study Updates

The registry is designed to be the most comprehensive database of clinical and genomic information from thousands of patients with MM in the first at-home genomic testing program.

Oncology Times - Latest Articles

source list reference